Although such associations have not yet been systematically investigated in Korean populations, the national prevalence of diabetes continues to rise—affecting approximately 15% of adults aged ≥ 30 years during 2021–2022 [3]—and the prescription of SGLT2 inhibitors has expanded rapidly in recent years, increasing nearly nine-fold between 2015 and 2020 (1.2% → 10.5%) [13,14]. Here, SLC5A2 is linked to diabetes mellitus.